Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00305747 · ClinicalTrials.gov registry record · Phase 1

Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy

A Phase 1 study of Prostate Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
2
Study locations

NCT00305747 is a Phase 1 study of Prostate Cancer that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 12 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00305747, a Phase 1 study of Prostate Cancer, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
2
Study locations

Study Summary

RATIONALE: Diindolylmethane may slow the growth of prostate cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of diindolylmethane in treating patients with nonmetastatic prostate cancer that has not responded to previous hormone therapy.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG BR-DIM

Study Locations (2)

Michigan

  • Barbara Ann Karmanos Cancer Institute - Detroit
  • Weisberg Cancer Treatment Center - Detroit

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2005-08
Est. Completion 2010-09
Phase Phase 1

Sponsor

Barbara Ann Karmanos Cancer Institute

139 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00305747

The ClinicalTrials.gov registry entry for NCT00305747 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which BR-DIM is the first listed.

NCT00305747 reports 2 study locations spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT00305747 about?

NCT00305747 is a clinical study titled "Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy". RATIONALE: Diindolylmethane may slow the growth of prostate cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of diindolylmethane in treating patients with nonmetastatic prostate cancer that has not responded to previous hormone therapy.

What is the current status of trial NCT00305747?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2005-08. Estimated completion is 2010-09.

What conditions does trial NCT00305747 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00305747?

The interventions under investigation include: BR-DIM (DRUG).

Who is sponsoring clinical trial NCT00305747?

This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00305747 being conducted?

This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.